Vanda director sells 30,000 VNDA shares
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vanda Pharmaceuticals director Honore Tage sold 30,000 shares of common stock in an open-market transaction at a price of $8.03 per share. After this sale, Tage directly owns 93,469 shares of Vanda Pharmaceuticals common stock.
Insider Trade Summary
Net Seller: 30,000 shares
Net Sell
1 txn
Insider
Honore Tage
Role
Director
Sold
30,000 shs ($241K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 30,000 | $8.03 | $241K |
Holdings After Transaction:
Common Stock — 93,469 shares (Direct)
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Vanda Pharmaceuticals (VNDA) director Honore Tage report on this Form 4?
Honore Tage reported selling 30,000 shares of Vanda Pharmaceuticals common stock. The transaction was an open-market sale at $8.03 per share, and it changed Tage’s direct holdings to 93,469 shares following the sale.
Was the Vanda Pharmaceuticals (VNDA) insider transaction a buy or a sell?
The transaction was a sale of Vanda Pharmaceuticals common stock. Honore Tage executed an open-market sale, disposing of 30,000 shares at a reported price of $8.03 per share according to the Form 4 details.
What type of transaction did Vanda Pharmaceuticals (VNDA) report for Honore Tage?
The filing shows an open-market sale of common stock by director Honore Tage. Classified under transaction code “S,” it represents a standard sale transaction rather than an option exercise, gift, or other non-market-related equity movement.
Does the Vanda Pharmaceuticals (VNDA) Form 4 show direct or indirect ownership for Honore Tage?
The Form 4 identifies Honore Tage’s holdings as direct ownership. After the open-market sale of 30,000 shares, his directly held position in Vanda Pharmaceuticals common stock stands at 93,469 shares, as reported in the filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.